BACKGROUND: Ustekinumab (UST)is a fully human monoclonal antibody against IL-12/23 approved in Brazil for the treatment of moderate-to-severe Crohn’s disease (CD) in November 2017. U...
BACKGROUND: Despite the numerous advances in medical treatment, it is estimated that a significant percentage of patients with Crohn's disease (CD) requires bowel resection at least once....
1 Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Brazil, Ribeirao Preto, Brazil;
2 Ribeirao Preto Medical School, University of São Paulo, Braz...
BACKGROUND: Ustekinumab (UST)is a fully human monoclonal antibody against IL-12/23 approved in Brazil for the treatment of moderate-to-severe Crohn’s disease (CD) in November 2017. UST ha...